|Bid||21.00 x 300|
|Ask||35.00 x 100|
|Day's Range||24.75 - 26.00|
|52 Week Range||23.80 - 35.74|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.33|
Zai Lab Limited (NASDAQ:ZLAB), a USD$1.32B small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, andRead More...
In this article, I’m going to take a look at Zai Lab Limited’s (NASDAQ:ZLAB) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
SHANGHAI, China, Sept. 29, 2017-- Zai Lab Limited, a Shanghai-based innovative biopharmaceutical company, announced today that it has dosed the first patient in a Phase 3 registration trial to evaluate ...
Seven IPOs are scheduled to hit the public markets this week, including video streaming service Roku and specialty chemicals firm PQ Group, both valued at more than $1 billion before their IPOs.
NEW YORK, Sept. 22, 2017-- Zai Lab Limited announces the closing of its U.S. initial public offering of 9,583,333 American depositary shares at a price of US $18.00 per ADS, which includes the 1,250,000 ...
NEW YORK, Sept. 20, 2017-- Zai Lab Limited announces the pricing of its U.S. initial public offering of American depositary shares, raising gross proceeds of approximately US $150.0 million.. 8,333,333 ...
NEW YORK, Sept. 19, 2017-- Zai Lab Limited announces its intent to upsize its U.S. initial public offering of American depositary shares. Zai Lab now plans to offer and sell 8,000,000 ADSs. In addition, ...